40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W / 40.678631; -78.243038

Oyster Point Pharma, Inc.
Typesubsidiary
Nasdaq: OYST
IndustryBiotechnology
Founded2015[1]
Headquarters
Princeton, New Jersey
,
U.S.
Key people
Jeffrey Nau
(President and CEO)
Websitewww.oysterpointrx.com

Oyster Point Pharma, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.[2]

Products

The lead product of the company is Tyrvaya. In October 2021, it was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.[3]

Initial public offering and stock history

Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.[4] In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.[5][6]

In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.[7] In January 2023 Viatris acquired Oyster Point Pharma in an all-cash deal.[8]

References

  1. ↑ "SEC FORM S-1". Oyster Point Pharma. Retrieved 27 April 2022.
  2. ↑ "Oyster Point Pharma Inc". Reuters. Retrieved 27 April 2022.
  3. ↑ Harrison, Laird (27 October 2021). "FDA Approves First Nasal Spray for Dry Eye". WenMD Health News. Retrieved 27 April 2022.
  4. ↑ Marinova, Polina (31 October 2019). "Fair's CEO Scott Painter Resigns as Car-Leasing Startup Seeks a Path to Profitability". Fortune. Retrieved 27 April 2022.
  5. ↑ Marinova, Polina (26 February 2019). "Term Sheet — Tuesday, February 26". Fortune. Retrieved 27 April 2022.
  6. ↑ Gormley, Brian (26 February 2019). "Oyster Point Pharma Banks $93 Million for Dry Eye Therapy". Wall Street Journal Pro. Retrieved 27 April 2022.
  7. ↑ Vecchione, Anthony (31 October 2019). "Oyster Point Pharma shares gain in IPO". NJBIZ. Retrieved 27 April 2022.
  8. ↑ "Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division" (Press release). PR Newswire. January 3, 2023.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.